ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $3.3B | $2.9B | $2.7B | $2.4B | $2.2B | $2.4B | $1.8B | $1.5B | $1.1B | $1.7B | $618M | $1.0B | $602M | $246M | $123M | $146M | $233M | $281M | $192M |
| Inventory | $97M | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | — | — | — | — | — | — | — | — | — | — |
| Current assets | $4.6B | $4.1B | $3.3B | $3.0B | $2.7B | $2.8B | $2.6B | $1.7B | $1.2B | $1.8B | $672M | $1.1B | $746M | $254M | $126M | $152M | $254M | $294M | — |
| Intangible assets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $275K | $448K | $622K | — |
| Total assets | $5.6B | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B | $3.4B | $2.4B | $1.6B | $2.0B | $1.3B | $1.4B | $1.1B | $421M | $288M | $282M | $393M | $481M | — |
| Current liabilities | $1.5B | $1.5B | $1.2B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | $54M | $48M | $81M | $102M | $111M | — |
| Long-term debt | — | — | — | — | — | $676M | $191M | — | — | — | — | — | — | — | — | — | — | — | — |
| Total liabilities | $4.2B | $4.2B | $4.2B | $4.1B | $3.7B | $3.1B | $2.4B | $956M | $273M | $228M | $343M | $122M | $143M | $150M | $153M | $164M | $235M | $303M | — |
| Shareholders' equity | $1.4B | $789M | $67M | −$221M | −$158M | $588M | $1.0B | $1.4B | $1.3B | $1.8B | $920M | $1.3B | $936M | $270M | $134M | $118M | $158M | $178M | $202M |
| Shares outstanding | 133.8M | 132.6M | 129.5M | 125.9M | 124.1M | 120.2M | 117.0M | 112.6M | 106.3M | 99.9M | 86.0M | 85.1M | 83.8M | 63.9M | 61.9M | 43.2M | 42.3M | — | — |
| Current ratio | 3.05 | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 | 4.47 | 4.87 | 6.69 | 12.23 | 5.10 | 17.80 | 7.83 | 4.72 | 2.60 | 1.88 | 2.49 | 2.65 | — |